CSIMarket Company Name, Ticker, Industry, else..
 
Humacyte Inc   (NASDAQ: HUMA)
 
Price: $0.5651 $0.00 -0.335%
Day's High: $0.5878000259399414 Week Perf: -6.6 %
Day's Low: $ 0.56 30 Day Perf: -15.02 %
Volume (M): 1,031,509 52 Wk High: $ 2.55
Volume (M$): $ 0 52 Wk Avg: $1.06
Open: $0.58 52 Wk Low: $0.53



 Market Capitalization (Millions $) 132
 Shares Outstanding (Millions) 234
 Employees 184
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -97
 Cash Flow (TTM) (Millions $) -39
 Capital Exp. (TTM) (Millions $) 0

Business Description


Humacyte Inc is a biotechnology company that specializes in developing and manufacturing a groundbreaking regenerative medicine platform. The company focuses on the development of universal tissue and blood vessel replacements for patients in need. Their proprietary technology involves growing blood vessels in a lab, using a human cell-based tissue engineering platform. Humacyte's goal is to provide patients with long-lasting, off-the-shelf, and biocompatible blood vessels that can be used in various surgical procedures, such as by-pass surgeries or replacement of damaged blood vessels. Their innovative approach offers potential solutions to disorders requiring vascular access or complex vascular surgeries.


   Company Address: 2525 East North Carolina Highway 54 Durham 27713 NC
   Company Phone Number: 313-9633   Stock Exchange / Ticker: NASDAQ HUMA


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AURA   -6.8%    
FATE   -4.9%    
LCTX   -8.11%    
OCGN   -21.85%    
RGNX   -10.83%    
VIVS        7.07% 
• View Complete Report
   



Clinical Study

Humacyte Highlights Innovative Progress in Bioengineered Tissues at Major Vascular Events A New Era for Vascular Surg...

Published Thu, Nov 13 2025 1:24 PM UTC

In an exceptional showcase of innovation and scientific advancement, Humacyte, Inc. (Nasdaq: HUMA), a pioneering biotechnology company dedicated to the development of bioengineered human tissues, has announced its participation in the prestigious 52nd Annual Symposium on Vascular and Endovascular Issues, Techniques, and Horizons (VEITHsymposium). Scheduled to take place from...
Shares

Humacyte, Inc. Prices $50 Million Stock Offering Amid Recent Growth in Share Price,

Published Wed, Mar 26 2025 12:35 AM UTC

Humacyte, Inc. Prices $50 Million Stock Offering Amid Recent Growth in Share PriceDURHAM, N.C. Humacyte, Inc. (Nasdaq: HUMA), a biotechnology firm specializing in the development of bioengineered human tissues for medical applications, has announced the pricing of a public offering for 25 million shares of its common stock at a price of $2.00 per share. This offering is ex...
Management Announcement

Humacytes Revolutionary Breakthrough: A Double-Edged Sword Amidst Financial Struggles

Published Fri, Dec 20 2024 3:47 AM UTC

In a significant advancement for vascular medicine, Humacyte Inc. has secured FDA approval for its innovative product, SYMVESS, an acellular tissue-engineered vessel designed specifically to treat extremity vascular trauma. Heralded as a first-in-class bioengineered human tissue, SYMVESS is designed to be a universally implantable vascular conduit aimed at improving the out...
Announcement

Under Legal and Financial Pressure Humacyte Inc.s Path Forward in the Biopharmaceutical Sector,

Published Wed, Nov 20 2024 2:00 AM UTC

Humacyte Inc.: Navigating Legal Challenges and Stagnant Revenue Growth in the Biopharmaceutical Landscape In recent developments concerning Humacyte Inc. a class action lawsuit has been filed against the company in the United States District Court for the Middle District of North Carolina. This legal action represents potential challenges for the biopharmaceutical company, w...
Clinical Study

Humacytes Advanced Tissue Engineering Sets New Standard for Vascular Repair and Diabetes Care,

Published Thu, Nov 21 2024 1:00 PM UTC

Revolutionary Advances in Vascular Repair: Humacyte s ATEV and BVP Programs Presented in JAMA SurgeryIn a landmark publication, Humacyte Inc. announced its innovative Acellular Tissue Engineered Vessel (ATEV) has demonstrated compelling benefits in repairing arterial injuries, as published in the prestigious JAMA Surgery. This development marks a significant breakthrough in...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 4.40
Price to Sales (Expected) -
Price to Book 4.23
PEG (TTM) -

Financial Strength Current
Quick Ratio 5.35
Working Capital Ratio 6.21
Leverage Ratio (MRQ) 3.42
Total Debt to Equity 1.26
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -0.5 $
Revenues (TTM) 0.13 $
Cash Flow (TTM) -
Cash 0.34 $
Book Value 0.13 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -525,734
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) 1.03
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Humacyte Inc's Segments
Product    -18.93 % of total Revenue
Product and Service Other    -0.04 % of total Revenue





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.